What Causes Lupus Flares?

Fernández, David; Kirou, Kyriakos A.

doi:10.1007/s11926-016-0562-3

Cited by 54 publications

(50 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with diverse manifestations, characterized by periods of remission and flare. 1,2 There is no cure for SLE; however, several classes of drugs are used to manage the disease, including corticosteroid (CS), antimalarial (AM), and immunosuppressant (IS) agents and non-steroidal anti-inflammatory drugs (NSAIDs). 3 Belimumab is a human IgG1λ monoclonal antibody approved for the treatment of adult patients with active, autoantibody-positive SLE who are receiving standard SLE therapy (referred to as standard of care [SoC]).…”

Section: Introductionmentioning

confidence: 99%

Patient- and Physician-reported Satisfaction With Systemic Lupus Erythematosus Treatment in US Clinical Practice

Pascoe

Lobosco

Bell

et al. 2017

Clinical Therapeutics

View full text Add to dashboard Cite

Purpose: This two-part study comprised two descriptive, cross-sectional surveys to evaluate treatment satisfaction among patients with systemic lupus erythematosus (SLE) and their physicians from US clinical practices. The Lupus Plus Project (LPP; part one) involved belimumab-containing regimens; the Disease Specific Program (DSP; part two) included all treatments and was designed to build on the body of evidence from part one.Methods: The LPP recruited patients receiving belimumab, and comprised 2 paper questionnaires: a patient self-completion questionnaire (PSC) and a patient record form (PRF) completed by the physician. The DSP enrolled patients with SLE receiving any treatment and comprised four parts: a PSC, a PRF completed by the physician after patient consultation, face-to-face physician interviews, and a workload form completed by the physicians to indicate their total SLE patient workload.The key objective of this study was to assess physician and patient satisfaction with current treatment.Findings: From the PSCs, data regarding patientreported satisfaction with current treatment were available for 263 patients who were receiving belimumab combination therapy (LPP) and 250 patients who were receiving non-belimumab treatment (DSP). The majority of patients (belimumab, 86.3% [227/263]; non-belimumab, 78.4% [196/250]) responded positively (at least "somewhat satisfied") when asked about current treatment satisfaction, as did physicians (belimumab, 82.9% [311/375]; non-belimumab, 74.3% [326/439]). In multivariate analysis, factors most strongly associated with

show abstract

Section: Introductionmentioning

confidence: 99%

Patient- and Physician-reported Satisfaction With Systemic Lupus Erythematosus Treatment in US Clinical Practice

Pascoe

Lobosco

Bell

et al. 2017

Clinical Therapeutics

View full text Add to dashboard Cite

show abstract

“…Such haplogroups are characterized by sets of polymorphisms in mtDNA; we mentioned the ND3 encoding N haplogroup above. Other specific haplogroups have been associated with longevity and altered risk of specific disorders [ 229 , 230 , 231 , 232 , 233 , 234 , 235 , 236 ].…”

Section: Genetics Of Mitochondrial Dnamentioning

confidence: 99%

Intimate Relations—Mitochondria and Ageing

Webb¹,

Sideris²

2020

IJMS

View full text Add to dashboard Cite

Mitochondrial dysfunction is associated with ageing, but the detailed causal relationship between the two is still unclear. We review the major phenomenological manifestations of mitochondrial age-related dysfunction including biochemical, regulatory and energetic features. We conclude that the complexity of these processes and their inter-relationships are still not fully understood and at this point it seems unlikely that a single linear cause and effect relationship between any specific aspect of mitochondrial biology and ageing can be established in either direction.

show abstract

“…SLE is a multisystem autoimmune disease associated with the presence of pathogenic autoantibodies and the overexpression of B cell-activating factor, formerly known as B-lymphocyte stimulator [ 1 , 2 ]. Self-reactive antibodies mediate tissue damage in multiple organs [ 3 ], often in the form of acute flares [ 4 ], which if left untreated can lead to fatal complications, including renal failure [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

“…SLE treatments include low-dose CS and antimalarial medications for mild disease, with high-dose CS and immunosuppressive medications for moderate-to-severe disease [ 6 ]. Although these treatments have improved the long-term survival for SLE [ 7 ], patients are at risk of developing irreversible organ damage due to high disease activity (HDA) [ 4 , 8 ] and long-term use of CS and immunosuppressants [ 9–11 ]. Prevention of long-term organ damage is therefore a key unmet need in SLE.…”

Section: Introductionmentioning

confidence: 99%

Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension

Vollenhoven¹,

Navarra

Levy

et al. 2019

Rheumatology

View full text Add to dashboard Cite

Objective This extension study of the Phase III, randomized, placebo-controlled Belimumab International SLE Study (BLISS)-52 and BLISS-76 studies allowed non-US patients with SLE to continue belimumab treatment, in order to evaluate its long-term safety and tolerability including organ damage accrual. Methods In this multicentre, long-term extension study (GlaxoSmithKline Study BEL112234) patients received i.v. belimumab every 4 weeks plus standard therapy. Adverse events (AEs) were assessed monthly and safety-associated laboratory parameters were assessed at regular intervals. Organ damage (SLICC/ACR Damage Index) was assessed every 48 weeks. The study continued until belimumab was commercially available, with a subsequent 8-week follow-up period. Results A total of 738 patients entered the extension study and 735/738 (99.6%) received one or more doses of belimumab. Annual incidence of AEs, including serious and severe AEs, remained stable or declined over time. Sixty-nine (9.4%) patients experienced an AE resulting in discontinuation of belimumab or withdrawal from the study. Eleven deaths occurred (and two during post-treatment follow-up), including one (cardiogenic shock) considered possibly related to belimumab. Laboratory parameters generally remained stable. The mean (s.d.) SLICC/ACR Damage Index score was 0.6 (1.02) at baseline (prior to the first dose of belimumab) and remained stable. At study year 8, 57/65 (87.7%) patients had no change in SLICC/ACR Damage Index score from baseline, indicating low organ damage accrual. Conclusion Belimumab displayed a stable safety profile with no new safety signals. There was minimal organ damage progression over 8 years. Trial registration ClinicalTrials.gov, https://clinicaltrials.gov, NCT00424476 (BLISS-52), NCT00410384 (BLISS-76), NCT00732940 (BEL112232), NCT00712933 (BEL112234).

show abstract

What Causes Lupus Flares?

Cited by 54 publications

References 96 publications

Patient- and Physician-reported Satisfaction With Systemic Lupus Erythematosus Treatment in US Clinical Practice

Patient- and Physician-reported Satisfaction With Systemic Lupus Erythematosus Treatment in US Clinical Practice

Intimate Relations—Mitochondria and Ageing

Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension

Contact Info

Product

Resources

About